Your browser doesn't support javascript.
loading
Next generation L2-based HPV vaccines cross-protect against cutaneous papillomavirus infection and tumor development.
Ahmels, Melinda; Mariz, Filipe C; Braspenning-Wesch, Ilona; Stephan, Sonja; Huber, Bettina; Schmidt, Gabriele; Cao, Rui; Müller, Martin; Kirnbauer, Reinhard; Rösl, Frank; Hasche, Daniel.
Afiliación
  • Ahmels M; Division of Viral Transformation Mechanisms, Research Program "Infection, Inflammation and Cancer", German Cancer Research Center (DKFZ), Heidelberg, Germany.
  • Mariz FC; Research Group Tumorvirus-specific Vaccination Strategies, Research Program "Infection, Inflammation and Cancer", German Cancer Research Center (DKFZ), Heidelberg, Germany.
  • Braspenning-Wesch I; Division of Viral Transformation Mechanisms, Research Program "Infection, Inflammation and Cancer", German Cancer Research Center (DKFZ), Heidelberg, Germany.
  • Stephan S; Division of Viral Transformation Mechanisms, Research Program "Infection, Inflammation and Cancer", German Cancer Research Center (DKFZ), Heidelberg, Germany.
  • Huber B; Laboratory of Viral Oncology, Department of Dermatology, Medical University of Vienna, Vienna, Austria.
  • Schmidt G; Core Facility Unit Light Microscopy, German Cancer Research Center (DKFZ), Heidelberg, Germany.
  • Cao R; Division of Viral Transformation Mechanisms, Research Program "Infection, Inflammation and Cancer", German Cancer Research Center (DKFZ), Heidelberg, Germany.
  • Müller M; Research Group Tumorvirus-specific Vaccination Strategies, Research Program "Infection, Inflammation and Cancer", German Cancer Research Center (DKFZ), Heidelberg, Germany.
  • Kirnbauer R; Laboratory of Viral Oncology, Department of Dermatology, Medical University of Vienna, Vienna, Austria.
  • Rösl F; Division of Viral Transformation Mechanisms, Research Program "Infection, Inflammation and Cancer", German Cancer Research Center (DKFZ), Heidelberg, Germany.
  • Hasche D; Division of Viral Transformation Mechanisms, Research Program "Infection, Inflammation and Cancer", German Cancer Research Center (DKFZ), Heidelberg, Germany.
Front Immunol ; 13: 1010790, 2022.
Article en En | MEDLINE | ID: mdl-36263027
Asunto(s)
Palabras clave
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Asunto principal: Proteínas Oncogénicas Virales / Infecciones por Papillomavirus / Vacunas contra Papillomavirus / Vacunas de Partículas Similares a Virus / Neoplasias Límite: Animals / Humans Idioma: En Revista: Front Immunol Año: 2022 Tipo del documento: Article País de afiliación: Alemania
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Asunto principal: Proteínas Oncogénicas Virales / Infecciones por Papillomavirus / Vacunas contra Papillomavirus / Vacunas de Partículas Similares a Virus / Neoplasias Límite: Animals / Humans Idioma: En Revista: Front Immunol Año: 2022 Tipo del documento: Article País de afiliación: Alemania